Indiva Gains Approval to Commence Cannabis Sales

Visit the Indiva Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

INDIVA Receives Sales License and Nears 50% Completion of its Facility Expansion

LONDON, ON, Aug. 13, 2018 /CNW/ – INDIVA Limited (the “Company” or “INDIVA”) (TSXV:NDVA) is pleased to announce its wholly-owned subsidiary, Indiva Inc., received its license to sell cannabis. In addition, INDIVA is pleased to report that construction is fully underway at its London, ON growing facility.

Sales License

INDIVA is now able to sell dried cannabis flowers in accordance with Canada’s Access to Cannabis for Medical Purposes Regulation.

We are very excited to be granted our sales license from Health Canada. I would like to thank all of our employees, shareholders and stakeholders for their tireless efforts and dedication.

Niel Marotta, CEO, INDIVA

INDIVA’s cannabis products are expected to be available for purchase at www.indiva.com from the online store to be launched this fall.

Expansion of Licensed Facility Nears 50% Complete

INDIVA commenced construction on the expansion of its London licensed facility in the spring of 2018. INDIVA is now pleased to report that construction is progressing well and is nearly 50% complete. While full completion is expected in Q1 of 2019, additional production capacity is expected to come online in Q4 of 2018 with full production capacity to be reached in 2019.

The fully-funded facility expansion includes eight additional flower rooms, extraction and processing facilities and a laboratory for research, development, testing and tissue culture. INDIVA’s current licensed facility is 10,000 square feet, however upon completion of construction it will grow to approximately 40,000 square feet.

At full capacity, INDIVA expects its London facility to produce more than 3,000 kgs of high quality dry flower per year, process tons of cannabis material into oils and other derivative materials upon receipt of applicable regulatory approvals, and to produce consumable products, including Bhang Chocolates and Ruby Cannabis Sugars, when permitted by applicable law.

About INDIVA

INDIVA is a Canadian supplier of high quality, medical grade cannabis. INDIVA’s strain selection, cultivation and client care processes combine the know-how and experience of an internationally recognized and award-winning grow-team with GMP-compliant quality assurance standard operating procedures.

INDIVA’s wholly owned subsidiary is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulation (“ACMPR”) with its first indoor cannabis production facility located in London, Ontario.

INDIVA aims to become a global marijuana brand recognized for high quality cannabis products and excellent client care. As marijuana laws liberalize in Canada, INDIVA will expand its product offering to include safe edibles and other client-friendly cannabis products. In addition, as marijuana laws liberalize internationally, INDIVA will use its Canadian operations as a platform to open new markets for its cannabis products.

Original press release

The most reliable, fact-based information on Indiva found only on its Investor Dashboard.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter